GANTRISIN PEDIATRIC
LOE ApproachingNDAORALSUSPENSION
Approved
Dec 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANTRISIN PEDIATRIC is an oral suspension antibiotic formulation approved in 1953 for pediatric patients. The drug represents a legacy anti-infective product with established clinical utility in treating bacterial infections in children. Specific indications and mechanism of action data are not available in current records.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching; commercial teams likely focused on harvest strategy and cost management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GANTRISIN PEDIATRIC offers limited career growth potential given the product's LOE-approaching status and minimal linked job openings. Professionals on this team should expect focus on operational efficiency and cost containment rather than innovation or market expansion.
Brand ManagerSales Representative
Worked on GANTRISIN PEDIATRIC at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.